Long non‐coding RNAs as potential biomarkers in the prognosis and diagnosis of lung cancer: A review and target analysis

Abstract

Long non-coding RNAs (lncRNA) have been emerged as a novel class of molecular regulators in cancer. They are dysregulated in many types of cancer; however, there is not enough knowledge available on their expression and functional profiles. Lung cancer is the leading cause of the cancer deaths worldwide. Generally, lncRNAs may be associated with lung tumor pathogenesis and they may act as biomarkers for the cancer prognosis and diagnosis. Compared to other invasive prognostic and diagnostic methods, detection of lncRNAs might be a user-friendly and noninvasive method. In this review article, we selected 27 tumor-associated lncRNAs by literature reviewing to further discussing in detail for using as diagnostic and prognostic biomarkers in lung cancer. Also, in an in silico target analysis, the "Experimentally supported functional regulation" approach of the LncTarD web tool was used to identifying the target genes and regulatory mechanisms of the selected lncRNAs. The reports on diagnostic and prognostic potential of all selected lncRNAs were discussed. However, the target genes and regulatory mechanisms of the 22 lncRNAs were identified by in silico analysis and we found the pathways that are controlled by each target group of lncRNAs. They use epigenetic mechanisms, ceRNA mechanisms, protein interaction and sponge mechanism. Also, 10, 23, 5, and 28 target genes for each of these mechanisms were identified, respectively. Finally, each group of target genes controls 50, 12, 7, and 2 molecular pathways, respectively. In conclusion, LncRNAs could be used as

Decreased HLF Expression Predicts Poor Survival in Lung Adenocarcinoma

“…The pathogenesis of lung cancer is complex and involves multiple causes and genes [ 4 ]. Many studies are focusing on the pathological mechanism of LUAD [ 1 , 4 ]. However, the cause of lung cancer is still unclear, and there is no cure for it [ 2 ].…”

The Efficacy of 18F-FDG PET/CT and Superparamagnetic Nanoferric Oxide MRI in the Diagnosis of Lung Cancer and the Value of 18F-FDG PET/CT in the Prediction of Lymph Node Metastasis

“…(1) in line with clinical diagnostic criteria for lung cancer [11], (2) no treatment prior to 18F-FDG PET/CT and superparamagnetic nanoiron oxide MRI, and (3) complete clinical data. Failing to be chosen criteria are as follows: (1) the presence of coagulation dysfunction or malignant tumor; (2) organic lesions of the heart, liver, and kidney organs; and…”

“…After being approved by the Medical Ethics Committee, patients with primary lung cancer receiving treatment from February 2017 to August 2020 were voted as the subjects of this study. Selection criteria are as follows: (1) in line with clinical diagnostic criteria for lung cancer [ 11 ], (2) no treatment prior to 18F-FDG PET/CT and superparamagnetic nanoiron oxide MRI, and (3) complete clinical data. Failing to be chosen criteria are as follows: (1) the presence of coagulation dysfunction or malignant tumor; (2) organic lesions of the heart, liver, and kidney organs; and (3) abnormal hematopoietic function.…”

ELK4-mediated lncRNA SNHG22 promotes gastric cancer progression through interacting with EZH2 and regulating miR-200c-3p/Notch1 axis

“…At the post-transcriptional level, lncRNAs and miRNAs networks control the display of numbers of target genes. This ceRNA mechanisms emerged as imperative regulator for target genes 35,37 . By online predictive tools and following RIP or luciferase activity assays, we discovered miR-200c-3p as the sponging miRNA of SNHG22.…”